Crizotinib versus chemotherapy: a real-world cost–effectiveness study in China

作者：Meijuan Huang, Yuke Tian, Mingmin He, Juan Liu, Li Ren, Youling Gong, Feng Peng, Yongsheng Wang, Zhenyu Ding, Jin Wang, Jiang Zhu, Yong Xu, Yongmei Liu, Lanting Li, You Lü · 发表于：Journal of Comparative Effectiveness Research · 年份：2020 · DOI：10.2217/cer-2019-0075 · 被引用次数：26 · 研究领域：Lung Cancer Treatments and Mutations、Gastric Cancer Management and Outcomes、Colorectal Cancer Treatments and Studies

Aim: To assess the cost–effectiveness of crizotinib verses platinum-based doublet chemotherapy as the first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) in the real-world setting. Methods: Data from 163 advanced ALK positive NSCLC patients were collected from West China Hospital, Sichuan University (Chengdu, China). They were categorized into two groups as treated with crizotinib (n = 83) or chemotherapy (n = 80) as a first-line therapy. The progression-free survival (PFS) as the primary clinical outcome, and the direct medical costs were collected from hospital information systems. Incremental cost–effectiveness ratio (ICER) was calculated with costs, quality-adjusted life-years, as well as the costs discounted at 3% annually. Additionally, two different kinds of medical insurance (MI) for pharma-economic assessment were considered. Results: Crizotinib improved PFS versus chemotherapy in ALK positive patients (median PFS 19.67 m vs 5.47 m; p < 0.001). Moreover, crizotinib obtained an ICER of US$36,285.39 before the end of 2016, when crizotinib, pemetrexed and anti-angiogenesis drugs were not MI covered. This is more than the willingness to pay threshold (three-times of gross domestic product per capita in mainland China or Sichuan Province). However, ICER was US$7321.16, which is less than willingness to pay, when crizotinib and all chemotherapy drugs were covered by MI from the end of 2016. Sensitivity analysis demonstra...